Kura Oncology, Inc. (KURA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+72.0%

$16.84

vs $9.79 price

Levered DCF

$13.85

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-2.79

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-3.27×	-4.31×	-6.91×	-6.11×	-7.11×	-19.33×	-9.11×	-8.16×
P/B	5.23×	1.81×	2.65×	1.98×	1.83×	2.84×	2.64×	3.07×
P/S	13.5×	13.93×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-2.84×	-3.2×	-6.88×	-5.88×	-6.53×	-16.01×	-8.28×	-7.72×
Gross margin	99.9%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	-449.9%	-358.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	-412.9%	-322.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	6.06×	9.46×	12.26×	18.56×	23.26×	24.49×	15.39×	13.31×
Debt / equity	0.12×	0.04×	0.04×	0.03×	0.01×	0.02×	0.04×	0.05×
Interest coverage	-200.81×	-119.33×	-107.04×	-610.76×	-317.05×	-158.99×	-116.34×	-64.83×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-160.0%	-42.1%	-38.4%	-32.3%	-25.8%	-14.7%	-28.9%	-37.5%
Return on invested capital	-48.8%	-28.2%	-39.9%	-32.2%	-25.5%	-14.7%	-29.7%	-37.3%
Return on assets	-37.7%	-22.9%	-34.0%	-29.8%	-24.4%	-13.8%	-26.1%	-33.1%
Free cash flow yield	-7.8%	17.8%	-11.9%	-13.3%	-11.4%	-4.2%	-9.5%	-9.8%
Earnings yield	-30.6%	-23.2%	-14.5%	-16.3%	-14.0%	-5.2%	-10.9%	-12.2%
Enterprise value	$782.3M	$542.6M	$1B	$793.6M	$845.1M	$1.4B	$558.4M	$485.5M
Net debt / EBITDA	0.47×	1.23×	0.13×	0.28×	0.65×	3.49×	0.27×	0.14×
Cash conversion cycle (days)	-29,414	0	-989	0	0	-5,180	0	-143,628